Contribute Try STAT+ Today

Under a contract awarded by the Trump administration, Emergent BioSolutions (EBS) was paid $27 million a month to make Covid-19 vaccines, but the company already knew of serious quality control problems at its Baltimore plant and failed to take any action, according to documents released by two House committees.

The manufacturing problems forced the company to destroy millions of doses of Johnson & Johnson (JNJ) Covid-19 vaccines earlier this year that were to have been made at the plant. In fact, a J&J audit conducted shortly after the contract was awarded found potential “weaknesses” and a “deficient” strategy for controlling contamination.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “Developing” indeed, mr ed! Thanks for this ‘breaking news’ in detail.

Comments are closed.